Cargando…

Time-series oligonucleotide count to assign antiviral siRNAs with long utility fit in the big data era

Oligonucleotides are key elements of nucleic acid therapeutics such as small interfering RNAs (siRNAs). Influenza and Ebolaviruses are zoonotic RNA viruses mutating very rapidly, and their sequence changes must be characterized intensively to design therapeutic oligonucleotides with long utility. Fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Wada, K, Wada, Y, Iwasaki, Y, Ikemura, T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5658673/
https://www.ncbi.nlm.nih.gov/pubmed/28905886
http://dx.doi.org/10.1038/gt.2017.76
_version_ 1783274053996380160
author Wada, K
Wada, Y
Iwasaki, Y
Ikemura, T
author_facet Wada, K
Wada, Y
Iwasaki, Y
Ikemura, T
author_sort Wada, K
collection PubMed
description Oligonucleotides are key elements of nucleic acid therapeutics such as small interfering RNAs (siRNAs). Influenza and Ebolaviruses are zoonotic RNA viruses mutating very rapidly, and their sequence changes must be characterized intensively to design therapeutic oligonucleotides with long utility. Focusing on a total of 182 experimentally validated siRNAs for influenza A, B and Ebolaviruses compiled by the siRNA database, we conducted time-series analyses of occurrences of siRNA targets in these viral genomes. Reflecting their high mutation rates, occurrences of target oligonucleotides evidently fluctuate in viral populations and often disappear. Time-series analysis of the one-base changed sequences derived from each original target identified the oligonucleotide that shows a compensatory increase and will potentially become the ‘awaiting-type oligonucleotide’; the combined use of this oligonucleotide with the original can provide therapeutics with long utility. This strategy is also useful for assigning diagnostic reverse transcription-PCR primers with long utility. SUPPLEMENTARY INFORMATION: The online version of this article (doi:10.1038/gt.2017.76) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5658673
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-56586732017-10-30 Time-series oligonucleotide count to assign antiviral siRNAs with long utility fit in the big data era Wada, K Wada, Y Iwasaki, Y Ikemura, T Gene Ther Article Oligonucleotides are key elements of nucleic acid therapeutics such as small interfering RNAs (siRNAs). Influenza and Ebolaviruses are zoonotic RNA viruses mutating very rapidly, and their sequence changes must be characterized intensively to design therapeutic oligonucleotides with long utility. Focusing on a total of 182 experimentally validated siRNAs for influenza A, B and Ebolaviruses compiled by the siRNA database, we conducted time-series analyses of occurrences of siRNA targets in these viral genomes. Reflecting their high mutation rates, occurrences of target oligonucleotides evidently fluctuate in viral populations and often disappear. Time-series analysis of the one-base changed sequences derived from each original target identified the oligonucleotide that shows a compensatory increase and will potentially become the ‘awaiting-type oligonucleotide’; the combined use of this oligonucleotide with the original can provide therapeutics with long utility. This strategy is also useful for assigning diagnostic reverse transcription-PCR primers with long utility. SUPPLEMENTARY INFORMATION: The online version of this article (doi:10.1038/gt.2017.76) contains supplementary material, which is available to authorized users. Nature Publishing Group UK 2017-09-14 2017 /pmc/articles/PMC5658673/ /pubmed/28905886 http://dx.doi.org/10.1038/gt.2017.76 Text en © The Author(s) 2017 This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/
spellingShingle Article
Wada, K
Wada, Y
Iwasaki, Y
Ikemura, T
Time-series oligonucleotide count to assign antiviral siRNAs with long utility fit in the big data era
title Time-series oligonucleotide count to assign antiviral siRNAs with long utility fit in the big data era
title_full Time-series oligonucleotide count to assign antiviral siRNAs with long utility fit in the big data era
title_fullStr Time-series oligonucleotide count to assign antiviral siRNAs with long utility fit in the big data era
title_full_unstemmed Time-series oligonucleotide count to assign antiviral siRNAs with long utility fit in the big data era
title_short Time-series oligonucleotide count to assign antiviral siRNAs with long utility fit in the big data era
title_sort time-series oligonucleotide count to assign antiviral sirnas with long utility fit in the big data era
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5658673/
https://www.ncbi.nlm.nih.gov/pubmed/28905886
http://dx.doi.org/10.1038/gt.2017.76
work_keys_str_mv AT wadak timeseriesoligonucleotidecounttoassignantiviralsirnaswithlongutilityfitinthebigdataera
AT waday timeseriesoligonucleotidecounttoassignantiviralsirnaswithlongutilityfitinthebigdataera
AT iwasakiy timeseriesoligonucleotidecounttoassignantiviralsirnaswithlongutilityfitinthebigdataera
AT ikemurat timeseriesoligonucleotidecounttoassignantiviralsirnaswithlongutilityfitinthebigdataera